TEMPOROMANDIBULAR JOINT CAPSULAR AND PERICAPSULAR INJECTION OF SCLEROSING AGENT AND ITS EFFECT ON THE MOUTH OPENING (AN EXPERIMENTAL STUDY)
ElRahmany, L., Elghamrawy, S., Mohamed, N., Raslan, H. (2019). TEMPOROMANDIBULAR JOINT CAPSULAR AND PERICAPSULAR INJECTION OF SCLEROSING AGENT AND ITS EFFECT ON THE MOUTH OPENING (AN EXPERIMENTAL STUDY). EKB Journal Management System, 44(2), 91-95. doi: 10.21608/adjalexu.2019.57370
Linda A. ElRahmany; Sherief H. Elghamrawy; Nevein S. Mohamed; Hanaa S. Raslan. "TEMPOROMANDIBULAR JOINT CAPSULAR AND PERICAPSULAR INJECTION OF SCLEROSING AGENT AND ITS EFFECT ON THE MOUTH OPENING (AN EXPERIMENTAL STUDY)". EKB Journal Management System, 44, 2, 2019, 91-95. doi: 10.21608/adjalexu.2019.57370
ElRahmany, L., Elghamrawy, S., Mohamed, N., Raslan, H. (2019). 'TEMPOROMANDIBULAR JOINT CAPSULAR AND PERICAPSULAR INJECTION OF SCLEROSING AGENT AND ITS EFFECT ON THE MOUTH OPENING (AN EXPERIMENTAL STUDY)', EKB Journal Management System, 44(2), pp. 91-95. doi: 10.21608/adjalexu.2019.57370
ElRahmany, L., Elghamrawy, S., Mohamed, N., Raslan, H. TEMPOROMANDIBULAR JOINT CAPSULAR AND PERICAPSULAR INJECTION OF SCLEROSING AGENT AND ITS EFFECT ON THE MOUTH OPENING (AN EXPERIMENTAL STUDY). EKB Journal Management System, 2019; 44(2): 91-95. doi: 10.21608/adjalexu.2019.57370

TEMPOROMANDIBULAR JOINT CAPSULAR AND PERICAPSULAR INJECTION OF SCLEROSING AGENT AND ITS EFFECT ON THE MOUTH OPENING (AN EXPERIMENTAL STUDY)

Alexandria Dental Journal
Article 15, Volume 44, Issue 2, August 2019, Page 91-95  XML PDF (319.79 K)
Document Type: Original Article
DOI: 10.21608/adjalexu.2019.57370
View on SCiNiTO View on SCiNiTO
Authors
Linda A. ElRahmany* 1; Sherief H. Elghamrawy2; Nevein S. Mohamed2; Hanaa S. Raslan3
1MSc Oral and Maxillofacial Surgery, Faculty of Dentistry, Alexandria University, Egypt
2Professor of Oral and Maxillofacial Surgery, Faculty of Dentistry, Alexandria University, Egypt.
3Professor of Oral Pathology, Faculty of Dentistry, Alexandria University, Egypt.
Abstract
INTRODUCTION: Recurrent Temporomandibular Joint (TMJ) dislocation is a relatively common problem encountered in the oral and maxillofacial clinics. Multiple interventions and injections had been described in the literature for TMJ dislocation treatment. Ethanolamine Oleate is a sclerosing agent that can be used in the treatment of TMJ dislocation by creation of inflammatory reaction which induces fibrosis, formation of adhesion and scar formation in the surrounding soft tissues. OBJECTIVES: The aim of this study was to evaluate Ethanolamine Oleate injection in TMJ capsular and pericapsular tissue and its effect on the mouth opening in rabbits. MATERIALS AND METHODS: This experimental study was conducted on eight New Zealand rabbits (approximately 6 months old and weight 2-3 Kg). They were divided into two groups: Group One (Study Group): Eight of these rabbits were injected by Ethanolamine Oleate into their Temporomandibular Joints capsule and pericapsular tissues in the right side. (Group two): left side was acting as a control group. Each two rabbits were sacrificed at intervals of two, four, six and eight weeks. TMJ capsule and pericapsular tissues were dissected and prepared to evaluate the histopathologic changes. RESULTS: The pericapsular tissue area surrounding the Temporomandibular Joint area showed similar histopathologic aspects in all samples. In fact, the pericapsular area showed angiogenesis with presence of fiber, new formed bone and cartilaginous hyaline tissue confirming the diagnosis of fibroblastic activity followed by zone of endochondral ossification and trabecular bone mixed with bone structures. CONCLUSIONS: Ethanolamine Oleate injection is a safe, simple, cost effective treatment of TMJ dislocation with minimal post-operative complication and foreign body reaction.
Keywords
TMJ; dislocation; Sclerosing
References
  1. Miloro M, Ghali GE, Larsen P, Waite P. Peterson's Principles of Oral and Maxillofacial Surgery. 3rd ed. USA: People's Medical Publishing House; 2012.
  2. Benoit P. History and physical examination for TMD. Temporomandibular Disorders 2nd ed. New York, NY: Churchill Livingstone; 1994.
  3. de Bont LG, Dijkgraaf LC, Stegenga B. Epidemiology and natural progression of articular temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:72-6.
  4. Hasson O, Nahlieli O. Autologous blood injection for treatment of recurrent temporomandibular joint dislocation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:390-3.
  5. Fernandez-Sanroman J. Surgical treatment of recurrent mandibular dislocation by augmentation of the articular eminence with cranial bone. J Oral Maxillofac Surg. 1997;55:333-8.
  6. Machon V, Abramowicz S, Paska J, Dolwick MF. Autologous blood injection for the treatment of chronic recurrent temporomandibular joint dislocation. J Oral Maxillofac Surg. 2009;67:114-9.
  7. Daif ET. Autologous blood injection as a new treatment modality for chronic recurrent temporomandibular joint dislocation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:31-6.
  8. Nitzan DW. Temporomandibular joint “open lock” versus condylar dislocation: signs and symptoms, imaging, treatment, and pathogenesis. J Oral Maxillofac Surg. 2002;60:506-11.
  9. Schiffman E, Look J, Hodges J, Swift J, Decker K, Hathaway K, et al. Randomized effectiveness study of four therapeutic strategies for TMJ closed lock. J Dent Res. 2007;86:58-63.
  10. Babadag M, Görgün S, Sahin M. Pre-and posttreatment analysis of clinical symptoms of patients with temporomandibular disorders. Quintessence Int. 2004;35:811-4.
  11. Aquilina P, Vickers R, McKellar G. Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral Maxillofac Surg. 2004;42:272-3.
  12. Matsushita K, Abe T, Fujiwara T. OK-432 (Picibanil) sclerotherapy for recurrent dislocation of the temporomandibular joint in elderly edentulous patients: Case reports. Br J Oral Maxillofac Surg. 2007;45:511-3.
  13. Pradhan L, Rahman QB. Effectiveness of Sclerotherapy with Ethanol Amine Oleate in Benign Oral and Perioral Vascular Lesions. BSMMU J. 2011;4:110-5.
  14. Kiripolsky MG. Commentary: More on ethanolamine oleate as a vascular sclerosant. Dermatol Surg. 2010;36:1153-4.
  15. Kato T, Shimoyama T, Nasu D, Kaneko T, Horie N, Kudo I. Autologous blood injection into the articular cavity for the treatment of recurrent temporomandibular joint dislocation: a case report. J Oral Sci. 2007;49:237- 9.
  16. Da Silva WB, Ribeiro ALR, de Menezes SAF, Pinheiro JdJV, de Melo Alves-Junior S. Oral capillary hemangioma: A clinical protocol of diagnosis and treatment in adults. Oral Maxillofac Surg. 2014;18:431- 7.
  17. Choi YH, Han MH, Kwon OK, Cha SH, Chang KH. Craniofacial cavernous venous malformations: percutaneous sclerotherapy with use of ethanolamine oleate. J Vasc Interv Radiol. 2002;13:475-82.
  18. Gulses A, Bayar GR, Aydintug YS, Sencimen M, Erdogan E, Agaoglu R. Histological evaluation of the changes in temporomandibular joint capsule and retrodiscal ligaments following autologous blood injection. J Craniomaxillofac Surg. 2013;41:316-20.
  19. Çandrl C, Yüce S, Yldrm S, Sert H. Histopathologic evaluation of autologous blood injection to the temporomandibular joint. J Craniofac Surg. 2011;22:2202-4.
  20. Ziegler CM, Haag C, Muhling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig. 2003;7:52-5.
  21. Hancı M, Karamese M, Tosun Z, Aktan TM, Duman S, Savaci N. Intra-articular platelet-rich plasma injection for the treatment of temporomandibular disorders and a comparison with arthrocentesis. Jof Craniomaxillofac Surg. 2015;43:162-6.
  22. Middleton KK, Barro V, Muller B, Terada S, Fu FH. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. Iowa Orthop J. 2012;32:150.
  23. Hakala RV, Ledermann KM. The use of prolotherapy for temporomandibular joint dysfunction. J Prolotherapy. 2010;2:439-46.
  24. Hong SK, Lee HJ, Seo JK, Lee D, Hwang SW, Sung HS. Reactive vascular lesions treated using ethanolamine oleate sclerotherapy. Dermatol Surg. 2010;36:1148-52.
  25. Alexander MD, McTaggart RA, Choudhri OA, Marcellus ML, Do HM. Percutaneous sclerotherapy with ethanolamine oleate for venous malformations of the head and neck. J Neurointerv Surg. 2014;6:695-8.
Statistics
Article View: 326
PDF Download: 1,192